Clinical-Microbiomics, CosmosID, DNASense, and MS-Omics have merged to form Cmbio. Please visit our new site cmbio.ioVisit cmbio.io
 

Blog

bt_bb_section_bottom_section_coverage_image

Copenhagen, Denmark, October 7th, 2024 – Clinical Microbiomics A/S (“CMC”), a leading innovator in multi-omics, bioinformatics and systems biology for the microbiome field, based in Copenhagen, Denmark, announces that the company has entered into a definitive agreement whereby Microba Life Sciences Limited (“Microba”) transfers its Research Services business unit to CMC. The deal supports CMC’s ambition to increase access to...

Clinical Microbiomics Launches Advanced Long-Read 16S, ITS, 18S, Isolate, and Metagenomics Sequencing Services

Offering Unparalleled Resolution and Quality in Microbial Analysis Copenhagen, Denmark — April 23, 2024 — Clinical Microbiomics, a leader in microbiome analysis, announces the launch of its advanced long-read sequencing services. Tailored to meet the stringent requirements of academic, clinical, and industrial researchers, the expanded offerings deliver unmatched insights into microbial communities, featuring the industry’s...

Resilient Biotics Announces Collaboration with CosmosID for Advanced Microbiome Exploration of the Respiratory Tract

Durham, NC (March 21, 2024 ) – Resilient Biotics, a leading microbiome platform company with a pipeline of products for maintaining respiratory tract health, is thrilled to announce a groundbreaking collaboration with CosmosID, a renowned microbiome analytics company. This joint effort aims to explore the intricate microbiome strains that colonize the respiratory tract tissues, a...

The gut microbiome has clear implications for health and disease. Recent evidence of this comes from a US FDA vote for approval of the microbiome-based drug RBX2660, created by Rebiotix Inc, A Ferring Company, to treat potentially deadly bacterial infections with Clostridium difficile (Cdiff). Cdiff is a common gut bacteria that may cause severe diarrhea...

Source   CosmosID, a leader in the field of microbiome analysis, announced today the launch of both long-read and hybrid sequencing offerings for comprehensive genome assembly and analysis. By utilizing both Oxford Nanopore Technologies (ONT) and Illumina based sequencing, CosmosID has developed optimized bioinformatic solutions for greater genome assembly capabilities, resulting in decreased number of...